April 30, 2020

COVID-19: Randomized, double-blind, placebo-controlled, multicenter trial of remdesivir

Editor's Note

In this randomized, double-blind, placebo-controlled, multicenter trial of remdesivir for the treatment of COVID-19, remdesivir was not associated with statistically significant clinical benefits.

For the analysis, 237 patients were randomly assigned to either a treatment group with remdesivir (158 patients) or placebo (79 patients).

Remdesivir use was not associated with a difference in time to clinical improvement. However, in patients with symptom duration of 10 days or less, those receiving remdesivir had a numerically  faster time to clinical improvement than those receiving placebo, but it was not statistically significant.

Adverse events were reported in 102 (66%) of remdesivir recipients vs 50 (64%) placebo recipients. Remdesivir was stopped early because of adverse events in 18 (12%) patients vs 4 (5%) of placebo patients who stopped early.

The numerical reduction in time to clinical improvement in those who were treated early requires confirmation in larger studies, the researchers say.


Join our community

Learn More
Video Spotlight
Live chat by BoldChat